Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 10/20 | 0.52 |
| ▸ | HSD17B2 | P37059 | 10/20 | 0.52 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | PTGES | O14684 | 1/20 | 0.45 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5343307 | 0.91 | MEN1 (0.53) | HSD17B1HSD17B2MEN1KMT2AHTT | |
| SCHEMBL2957633 | 0.90 | HSD17B1 (0.51) | HSD17B1HSD17B2MEN1KMT2AHTT | |
| SCHEMBL2951807 | 0.82 | MEN1 (0.48) | HSD17B1HSD17B2MEN1KMT2AHTT | |
| SCHEMBL2177213 | 0.81 | MEN1 (0.47) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL16912781 | 0.80 | CYP4F2 (0.43) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL66552 | 0.80 | CYP4F2 (0.46) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL2952954 | 0.80 | PTGER1 (0.42) | HSD17B1HSD17B2MEN1KMT2AHTT | |
| SCHEMBL8773482 | 0.79 | MEN1 (0.69) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL186800 | 0.79 | MEN1 (0.53) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL689321 | 0.78 | MEN1 (0.51) | MEN1KMT2AHTTL3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7767715-B2 | Sulfonamide derivatives for the treatment of diseases | PFIZER INC (US) | 2010-08-03 | — | — | US | disclosed |
| US-20090197912-A1 | Sulfonamide Derivatives for the Treatment of Diseases | BROWN ALAN DANIEL | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197912-A1 | Sulfonamide Derivatives for the Treatment of Diseases | SULT2A1, STS, SULT1A1 | HSD17B1 434/4885HSD17B2 509/4885GRIA2 2884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.